Cargando…
Duration of treatment in oncology clinical trials: does the duration change when the same drug moves from the experimental arm to the control arm?
BACKGROUND: When a new drug comes to the market, the incentive for the sponsoring company is to maximize the treatment duration in order for the patient to reap the full therapeutic benefit of the product and achieve a positive trial result. We sought to enumerate instances when an already-approved...
Autores principales: | Haslam, A., Olivier, T., Thawani, R., Prasad, V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271471/ https://www.ncbi.nlm.nih.gov/pubmed/35468562 http://dx.doi.org/10.1016/j.esmoop.2022.100480 |
Ejemplares similares
-
The Influence of Arm Swelling Duration on Shoulder Pathology in Breast Cancer Patients with Lymphedema
por: Jang, Dae-Hyun, et al.
Publicado: (2015) -
Single-arm trials for domestic oncology drug approvals in China
por: Zhang, Hong, et al.
Publicado: (2023) -
BMI Alterations and Prevalence of Overweight and Obesity Related to Service Duration at the German Armed Forces
por: Scheit, Lorenz, et al.
Publicado: (2023) -
Changes in the bilateral pulse transit time difference with a moving arm
por: Jiang, Xinge, et al.
Publicado: (2018) -
The duration aftereffect does not reflect adaptation to perceived duration
por: Maarseveen, Jim, et al.
Publicado: (2019)